Form 4 for CGON CG Oncology, Inc.
Accepted 2026-08-18 16:30:08 ET · period of report 2026-08-14 · accession 0001193125-26-355561 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-18 16:30 | 2026-08-14 | CGON | POST LEONARD E | Dir | M - OptEx | $0.6 | +1,000 | 1,000 | New | +$600 |
| DT | 2026-08-18 16:30 | 2026-08-14 | CGON | POST LEONARD E | Dir | S - Sale+OE | $74.54 | -1,000 | 0 | -100% | -$74.5K |
| DT | 2026-08-18 16:30 | 2026-08-14 | CGON | POST LEONARD E | Dir | M - OptEx | $0.00 | -1,000 | 104.1K | -1.0% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-14 | M | A | 1,000 | $0.6 | 1,000 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-14 | S | D | 1,000 | $74.54 | 0 | D | — | — | (F1) The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. |
| 3 | Derivative | Director Stock Option (right to buy) | 2026-08-14 | M | D | 1,000 | $0.00 | 104,077 | D | $0.6 · — to 2028-07-08 | 1,000 Common Stock | (F2) Fully vested |